{"id":"doi:10.3390/curroncol33100603","kind":"article","title":"Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study","authors":["Ren Z","Lu J"],"author_count":2,"year":2026,"published":"2026-10-07","venue":"Current oncology (Toronto, Ont.)","cited_by":0,"doi":"10.3390/curroncol33100603","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/curroncol33100603","archive_url":"https://space-kitty.com/papers/doi:10.3390/curroncol33100603","updated":null,"pmid":"42930170","pmcid":"PMC13703647","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC13703647/pdf","abstract":"Background Rheumatic immune-related adverse events (R-irAEs) after immune checkpoint inhibitor (ICI) therapy in lung cancer can be difficult to distinguish from cancer-related or degenerative musculoskeletal symptoms. Methods In this single-center retrospective cohort, we analyzed 768 ICI-treated patients and a nested questionnaire cohort to characterize rheumatologist-confirmed R-irAEs, baseline associated factors, and patient-reported outcomes. Missing baseline C-reactive protein (CRP) was handled using multiple imputation. Results New musculoskeletal symptoms occurred in 177 patients (23.0%), and 66 patients (8.6%) had confirmed R-irAEs. The leading phenotypes were inflammatory arthritis ( n = 22), inflammatory arthralgia ( n = 15), and polymyalgia rheumatica-like syndrome ( n = 13). In multivariable analysis, female sex (adjusted odds ratio [OR] 2.21, 95% confidence interval [CI] 1.31-3.74), baseline CRP > 10 mg/L (OR 2.08, 95% CI 1.14-3.81), and pre-existing autoimmune disease (OR 5.24, 95% CI 2.37-11.57) were associated with confirmed R-irAEs. Among 437 questionnaire responders, confirmed R-irAEs were associated with worse pain, morning stiffness, disability, fatigue, and health status than non-confirmed musculoskeletal symptoms (all Holm-adjusted p < 0.001). Conclusions Confirmed R-irAEs affected a measurable minority of ICI-treated patients with lung cancer and were associated with worse post-treatment patient-reported outcomes. Because baseline patient-reported outcomes were unavailable, these findings should not be interpreted as R-irAE-attributable change.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study\" by Ren Z, Lu J, https://doi.org/10.3390/curroncol33100603, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}